Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GB004 in Adult Subjects With Active Ulcerative Colitis

Next Previous
Search
Trial Profile

A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GB004 in Adult Subjects With Active Ulcerative Colitis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 004 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Gossamer Bio

    • Most Recent Events

    • 10 Jan 2022 Results published in the Alimentary Pharmacology and Therapeutics
    • 09 Aug 2021 According to a Gossamer Bio media release, Additional post-hoc analysis of clinical data from the study will be presented at the United European Gastroenterology (UEG) Virtual Week 2021.
    • 07 Jul 2021 According to a Gassamer Bio media release, data from this study will be presented at the 2021 Virtual Congress of the European Crohns and Colitis Organisation (ECCO),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top